Loading...
•
Jun 30, 2021
Fate Therapeutics Q2 2021 Earnings Report
Fate Therapeutics reported second quarter 2021 financial results and highlighted operational progress.
Key Takeaways
Fate Therapeutics reported revenue of $13.4 million for the second quarter of 2021, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $845.1 million as of June 30, 2021.
First patient treated for Relapsed / Refractory ALL in Phase 1 Clinical Trial of FT819.
FT516 Interim Phase 1 Data for Relapsed / Refractory Lymphoma Featured at ASCO; 8 of 11 Patients Achieved Objective Response.
Interim Phase 1 Data from FT516 and FT538 Programs for Relapsed / Refractory AML Highlighted at May Investor Event; 5 of 12 Patients Achieved Objective Response.
New Phase 1 Clinical Data from FT516 and FT596 Programs in Relapsed / Refractory Lymphoma to be Featured at Investor Event on August 19
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com